Table 4.
Estimated numbers of colposcopies, high-grade CIN and women not attending the two early recalls following the genotyping and non-genotyping triage protocols, by time of testing
| Time of testing | Screening test outcome at time of testing | HR-HPV genotyping protocol | Non-genotyping protocol | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Colposcopies | CIN2+(PPV) | CIN3+(PPV) | Not attending early recall | Colposcopies | CIN2+(PPV) | CIN3+(PPV) | Not attending early recall | ||
| Baseline test | HR-HPV+ and cyt+ | 5163 | 2135 (41%) | 1367 (26%) | 5163 | 2135 (41%) | 1367 (26%) | ||
| Early recall at 12 months | Not attending early recall | 1741 | 1741 | ||||||
| HR-HPV+ and cyt+ | 1369 | 479 (35%) | 272 (20%) | 1369 | 479 (35%) | 272 (20%) | |||
| HPV 16/18+ and cyt- | 1020 | 133 (13%) | 71 (7%) | ||||||
| Early recall at 24 months | Not attending early recall | 637 | 864 | ||||||
| HPV+ | 1198 | 123 (10%) | 59 (5%) | 1728 | 221 (13%) | 111 (6%) | |||
| Total | 8750 | 2869 (33%) | 1769 (20%) | 2378 | 8260 | 2835 (34%) | 1751 (21%) | 2626 | |
CIN cervical intraepithelial neoplasia, HR-HPV high-risk human papillomavirus, PPV positive predictive value